Company News: Nanohale AG acquires R&D and service units of Scil Technology GmbH

– Transaction creates new Nanohale subsidiary named Formycon GmbH –

Scil Technology GmbH and Nanohale AG today announced that Nanohale has acquired the entire R&D, contract development and manufacturing organization of Scil Technology GmbH in an asset deal, effective December 31, 2011. Employees and inventory of Scil Technology GmbH have become part of Formycon GmbH, a fully-owned subsidiary of Nanohale AG. The rights to the tissue regeneration projects, which were out-licensed by Scil Technology to Medtronic, Inc. and Sanofi, will remain with Scil Technology GmbH, which will be sustained as an independent company to manage its existing collaborations. Financial details have not been disclosed.

Scil Technology recently out-licensed its cartilage regeneration program for the treatment of osteoarthritis and osteochondral defects to Sanofi. The company has strong expertise in protein drug development, formulation and analytics, which is highly complementary to Nanohale´s existing protein formulation platform and will enable Nanohale to strengthen its biopharmaceutical development expertise.

Christian Nafe, CEO of Scil Technology, who was responsible for the transaction together with Klaus Binder (COO), said that the agreement creates an excellent exit opportunity for Scil Technology´s investors at BioNet Holding.